NVX 408

Drug Profile

NVX 408

Alternative Names: NVX-408

Latest Information Update: 09 Feb 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator NuvOx Pharma
  • Class Fluorocarbons
  • Mechanism of Action Oxygen carriers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haemorrhage; Haemorrhagic shock

Most Recent Events

  • 06 Jan 2017 Preclinical trials in Haemorrhage in USA (IV)
  • 06 Jan 2017 NuvOx Pharma and Jiangsu Nhwa Pharmaceutical agree to co-promote and co-develop NVX 408 in China for haemorrhagic shock and perioperative blood loss
  • 31 Aug 2014 Preclinical trials in Haemorrhagic shock in USA (IV) before August 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top